861 related articles for article (PubMed ID: 29893548)
1. Virological Basis for the Cure of Chronic Hepatitis B.
Hu J; Cheng J; Tang L; Hu Z; Luo Y; Li Y; Zhou T; Chang J; Guo JT
ACS Infect Dis; 2019 May; 5(5):659-674. PubMed ID: 29893548
[TBL] [Abstract][Full Text] [Related]
2. Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics.
Guo JT; Guo H
Antiviral Res; 2015 Oct; 122():91-100. PubMed ID: 26272257
[TBL] [Abstract][Full Text] [Related]
3. Cellular DNA Topoisomerases Are Required for the Synthesis of Hepatitis B Virus Covalently Closed Circular DNA.
Sheraz M; Cheng J; Tang L; Chang J; Guo JT
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867306
[TBL] [Abstract][Full Text] [Related]
4. The current status and future directions of hepatitis B antiviral drug discovery.
Tang L; Zhao Q; Wu S; Cheng J; Chang J; Guo JT
Expert Opin Drug Discov; 2017 Jan; 12(1):5-15. PubMed ID: 27797587
[TBL] [Abstract][Full Text] [Related]
5. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation.
Cai D; Mills C; Yu W; Yan R; Aldrich CE; Saputelli JR; Mason WS; Xu X; Guo JT; Block TM; Cuconati A; Guo H
Antimicrob Agents Chemother; 2012 Aug; 56(8):4277-88. PubMed ID: 22644022
[TBL] [Abstract][Full Text] [Related]
6. Antiviral strategies to eliminate hepatitis B virus covalently closed circular DNA (cccDNA).
Revill P; Locarnini S
Curr Opin Pharmacol; 2016 Oct; 30():144-150. PubMed ID: 27639371
[TBL] [Abstract][Full Text] [Related]
7. Involvement of Host ATR-CHK1 Pathway in Hepatitis B Virus Covalently Closed Circular DNA Formation.
Luo J; Luckenbaugh L; Hu H; Yan Z; Gao L; Hu J
mBio; 2020 Feb; 11(1):. PubMed ID: 32071277
[TBL] [Abstract][Full Text] [Related]
8. Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon?
Alonso S; Guerra AR; Carreira L; Ferrer JÁ; Gutiérrez ML; Fernandez-Rodriguez CM
BMC Gastroenterol; 2017 Dec; 17(1):168. PubMed ID: 29268704
[TBL] [Abstract][Full Text] [Related]
9. Latest developments in the treatment of hepatitis B.
Dandri M; Petersen J
Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
[TBL] [Abstract][Full Text] [Related]
10. A Role for the Host DNA Damage Response in Hepatitis B Virus cccDNA Formation-and Beyond?
Schreiner S; Nassal M
Viruses; 2017 May; 9(5):. PubMed ID: 28531167
[TBL] [Abstract][Full Text] [Related]
11. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B.
Nassal M
Gut; 2015 Dec; 64(12):1972-84. PubMed ID: 26048673
[TBL] [Abstract][Full Text] [Related]
12. T5 Exonuclease Hydrolysis of Hepatitis B Virus Replicative Intermediates Allows Reliable Quantification and Fast Drug Efficacy Testing of Covalently Closed Circular DNA by PCR.
Qu B; Ni Y; Lempp FA; Vondran FWR; Urban S
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232183
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of intrahepatic hepatitis B virus covalently closed circular DNA and total DNA in patients with acute hepatitis B and patients with chronic hepatitis B receiving anti‑viral treatment.
Ruan P; Zhou B; Dai X; Sun Z; Guo X; Huang J; Gong Z
Mol Med Rep; 2014 Apr; 9(4):1135-41. PubMed ID: 24566465
[TBL] [Abstract][Full Text] [Related]
14. Arsenic trioxide impacts hepatitis B virus core nuclear localization and efficiently interferes with HBV infection.
Hofmann S; Luther J; Plank V; Oswald A; Mai J; Simons I; Miller J; Falcone V; Hansen-Palmus L; Hengel H; Nassal M; Protzer U; Schreiner S
Microbiol Spectr; 2024 May; 12(5):e0378823. PubMed ID: 38567974
[TBL] [Abstract][Full Text] [Related]
15. An Effective Antiviral Approach Targeting Hepatitis B Virus with NJK14047, a Novel and Selective Biphenyl Amide p38 Mitogen-Activated Protein Kinase Inhibitor.
Kim SY; Kim H; Kim SW; Lee NR; Yi CM; Heo J; Kim BJ; Kim NJ; Inn KS
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559272
[TBL] [Abstract][Full Text] [Related]
16. Silencing hepatitis B virus covalently closed circular DNA: The potential of an epigenetic therapy approach.
Singh P; Kairuz D; Arbuthnot P; Bloom K
World J Gastroenterol; 2021 Jun; 27(23):3182-3207. PubMed ID: 34163105
[TBL] [Abstract][Full Text] [Related]
17. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication.
Dong C; Qu L; Wang H; Wei L; Dong Y; Xiong S
Antiviral Res; 2015 Jun; 118():110-7. PubMed ID: 25843425
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B Virus Covalently Closed Circular DNA Formation in Immortalized Mouse Hepatocytes Associated with Nucleocapsid Destabilization.
Cui X; Guo JT; Hu J
J Virol; 2015 Sep; 89(17):9021-8. PubMed ID: 26085156
[TBL] [Abstract][Full Text] [Related]
19. Dicoumarol, an NQO1 inhibitor, blocks cccDNA transcription by promoting degradation of HBx.
Cheng ST; Hu JL; Ren JH; Yu HB; Zhong S; Wai Wong VK; Kwan Law BY; Chen WX; Xu HM; Zhang ZZ; Cai XF; Hu Y; Zhang WL; Long QX; Ren F; Zhou HZ; Huang AL; Chen J
J Hepatol; 2021 Mar; 74(3):522-534. PubMed ID: 32987030
[TBL] [Abstract][Full Text] [Related]
20. Current Status and Challenges in Anti-Hepatitis B Virus Agents Based on Inactivation/Inhibition or Elimination of Hepatitis B Virus Covalently Closed Circular DNA.
Zhuang AQ; Chen Y; Chen SM; Liu WC; Li Y; Zhang WJ; Wu YH
Viruses; 2023 Nov; 15(12):. PubMed ID: 38140556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
